A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS

BACKGROUND. Acute respiratory distress syndrome (ARDS) is a prevalent disease with significant mortality for which no effective pharmacologic therapy exists. Low-dose inhaled carbon monoxide (iCO) confers cytoprotection in preclinical models of sepsis and ARDS. METHODS. We conducted a phase I dose e...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JCI Insight
Egile Nagusiak: Fredenburgh, Laura E., Perrella, Mark A., Barragan-Bradford, Diana, Hess, Dean R., Peters, Elizabeth, Welty-Wolf, Karen E., Kraft, Bryan D., Harris, R. Scott, Maurer, Rie, Nakahira, Kiichi, Oromendia, Clara, Davies, John D., Higuera, Angelica, Schiffer, Kristen T., Englert, Joshua A., Dieffenbach, Paul B., Berlin, David A., Lagambina, Susan, Bouthot, Mark, Sullivan, Andrew I., Nuccio, Paul F., Kone, Mamary T., Malik, Mona J., Porras, Maria Angelica Pabon, Finkelsztein, Eli, Winkler, Tilo, Hurwitz, Shelley, Serhan, Charles N., Piantadosi, Claude A., Baron, Rebecca M., Thompson, B. Taylor, Choi, Augustine M.K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2018
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6328240/
https://ncbi.nlm.nih.gov/pubmed/30518685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.124039
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak